Feb 28 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant says q4 was held back by pricing pressure, decline in dermatology prescriptions, egyptian currency
* Valeant reiterates August 2016 plan is to pay down $5 billion in debt within 18 months of that statement
* Valeant says has sold or agreed to sell 10 businesses to raise up to $2.7 billion to pay down debt
* Valeant sees continued pressure on dermatology volumes due to higher co-pays and managed care rebates in 2017 Further company coverage: VRX.TO